Share on StockTwits

Theravance Biopharma (NASDAQ:TBPH) announced its earnings results on Thursday. The company reported ($1.83) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.56) by $1.27, American Banking News reports.

A number of analysts have recently weighed in on TBPH shares. Analysts at Bank of America initiated coverage on shares of Theravance Biopharma in a research note on Friday, June 6th. They set a “buy” rating and a $34.00 price target on the stock. Analysts at Robert W. Baird initiated coverage on shares of Theravance Biopharma in a research note on Monday, June 2nd. They set a “neutral” rating and a $21.00 price target on the stock.

Shares of Theravance Biopharma (NASDAQ:TBPH) opened at 29.65 on Thursday. Theravance Biopharma has a 1-year low of $14.75 and a 1-year high of $35.675. The stock has a 50-day moving average of $31.29 and a 200-day moving average of $29.0. The company’s market cap is $956.5 million.

Theravance Biopharma, Inc, is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (NASDAQ:TBPH)/pain, respiratory disease, and gastrointestinal (GI) motility dysfunction.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.